LU Bioscience increases position in ProNoxis
"I value the progress made in ProNoxis" says Thomas Andersson, CEO of LU Bio. "We closely monitor the achievements and progress in our portfolio companies in order to successfully build our investment company within the field of bioscience."
ProNoxis is a spin out company from Redoxis and is focused on developing anti-inflammatory therapeutics that act through the NADPH oxidase complex (NOX2), an invention based on the research by Prof Rikard Holmdahl and Dr Peter Olofsson.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.